2,3-thiomorpholinedione-2-oxime derivatives and pharmaceutical
compositions containing them
    4.
    发明授权
    2,3-thiomorpholinedione-2-oxime derivatives and pharmaceutical compositions containing them 失效
    2,3-苯硫酚-2-氧化物衍生物和含有它们的药物组合物

    公开(公告)号:US5106846A

    公开(公告)日:1992-04-21

    申请号:US477999

    申请日:1990-07-10

    IPC分类号: A61K31/54 A61P1/04 C07D279/12

    CPC分类号: C07D279/12

    摘要: The present invention relates to compounds of the general formula (I), ##STR1## wherein R.sub.1 stands for hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy or nitro group;R.sub.2 means a C.sub.1-7 alkyl group optionally substituted by: a hydroxyl or oxo group; or an ester group containing 1 to 4 carbon atoms in the alkoxy moiety; or a C.sub.1-4 alkoxy, cyano, amino, C.sub.1-4 alkylamino, or dialkylamino group; or an acyl group containing 1 to 7 carbon atoms in the alkyl moiety; orR.sub.2 means an aryl-C.sub.1-7 alkyl group optionally bearing the substituents defined above for R.sub.2 in the alkyl chain and optionally substituted by halogen, nitro, C.sub.1-4 alkyl or alkoxy group in the benzene ring; orR.sub.2 represents an allyl, phenylallyl or phenylsulfonyl group, both latter groups optionally being substituted by halogen or a C.sub.1-4 alkyl group in the benzene ring; orR.sub.2 stands for a carbamoyl group substituted by one or two C.sub.1-4 alkyl group(s) or phenyl group on the nitrogen atom.The compounds according to the invention show a cytoprotective and acid secretion-inhibiting action and are effective against gastric and duodenal ulcers.

    摘要翻译: PCT No.PCT / HU88 / 00080 Sec。 371日期1990年7月10日 102(e)日期1990年7月10日PCT提交1988年12月13日PCT公布。 出版物WO89 / 05805 日本时间1989年6月29日。本发明涉及通式(I),其中R1代表氢,卤素,C1-4烷基,C1-4烷氧基或硝基的通式(I)的化合物。 R 2表示任选被羟基或氧代基取代的C 1-7烷基; 或在烷氧基部分含有1至4个碳原子的酯基; 或C 1-4烷氧基,氰基,氨基,C 1-4烷基氨基或二烷基氨基; 或在烷基部分含有1至7个碳原子的酰基; 或R 2表示任选具有上述对烷基链中的R 2定义并且任选被苯环中的卤素,硝基,C 1-4烷基或烷氧基取代的取代基的芳基-C 1-7烷基; 或R 2表示烯丙基,苯基烯丙基或苯基磺酰基,后两个基团任选被苯环中的卤素或C 1-4烷基取代; 或R 2表示被一个或两个C 1-4烷基或氮原子上的苯基取代的氨基甲酰基。 根据本发明的化合物显示出细胞保护和酸分泌抑制作用,并且对胃和十二指肠溃疡有效。

    [1,3]oxazino[4,3-a]-isoquinoline derivatives and pharmaceutical
compositions containing them
    7.
    发明授权
    [1,3]oxazino[4,3-a]-isoquinoline derivatives and pharmaceutical compositions containing them 失效
    [1,3]恶嗪并[4,3-a] - 异喹啉衍生物和含有它们的药物组合物

    公开(公告)号:US4623647A

    公开(公告)日:1986-11-18

    申请号:US664844

    申请日:1984-10-25

    CPC分类号: C07D498/04 C07D498/10

    摘要: The invention relates to new [1,3]oxazino[4,3-a]-isoquinoline derivatives of the formula (I) ##STR1## wherein R.sup.1 and R.sup.2 represent hydroxyl or alkoxy having from 1 to 6 carbon atoms,R.sup.3 is hydrogen, alkyl having from 1 to 8 carbon atoms, cycloakyl or cycloalkenyl having from 3 to 6 carbon atoms, optionally substituted phenyl, aralkyl having from 1 to 4 carbon atoms in the alkyl moiety or heteroaryl,R.sup.4 is hydrogen or alkyl having from 1 to 4 carbon atoms, orR.sup.3 and R.sup.4 together form a --(CH.sub.2).sub.n -- group, in which n is an integer from 3 to 7,R.sup.5 is hydroxyl, halogen or an ##STR2## group, in which R.sup.6 is optionally substituted phenyl,X is oxygen or sulfur,and salts thereof.According to another aspect of the invention there is provided a process for the preparation of these compounds. Compounds of formula (I) are pharmaceutically active. Pharmaceutical compositions containing them are also within the scope of the invention.

    摘要翻译: 本发明涉及式(I)的新的[1,3]恶嗪并[4,3-a] - 异喹啉衍生物其中R 1和R 2表示羟基或具有1至6个碳原子的烷氧基,R 3 是氢,具有1至8个碳原子的烷基,具有3至6个碳原子的环烷基或环烯基,任选取代的苯基,在烷基部分或杂芳基具有1至4个碳原子的芳烷基,R 4是氢或具有1 至4个碳原子,或者R 3和R 4一起形成 - (CH 2)n - 基团,其中n为3-7的整数,R 5为羟基,卤素或基团,其中R 6为任选取代的苯基 X是氧或硫,及其盐。 根据本发明的另一方面,提供了一种制备这些化合物的方法。 式(I)的化合物是药学活性的。 含有它们的药物组合物也在本发明的范围内。

    Condensed as-triazine derivatives and method of using the same
    8.
    发明授权
    Condensed as-triazine derivatives and method of using the same 失效
    缩合三嗪衍生物及其使用方法

    公开(公告)号:US4419355A

    公开(公告)日:1983-12-06

    申请号:US283971

    申请日:1981-07-16

    CPC分类号: C07D487/04

    摘要: The invention relates to new condensed as-triazine derivatives of the general formula (I) ##STR1## wherein Z represents a buta-1,3-dienyl group or a group of the formula (a), (b), (c) or (d) ##STR2## R.sub.1 denotes a C.sub.1-10 alkyl group, an oxo group or a C.sub.6-10 aryl or C.sub.6-10 aryl-(C.sub.1-3 alkyl) group optionally substituted by one or more identical or different substituents selected from the group consisting of amino, nitro, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy and halogen,R.sub.2 stands for hydrogen, C.sub.1-10 alkyl or amino,R.sub.3 represents hydrogen, C.sub.1-10 alkyl or C.sub.6-10 aryl or C.sub.6-10 aryl-(C.sub.1-3 alkyl) optionally substituted by one or more identical or different substituents selected from the group consisting of nitro, amino, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy and halogen,X.sup.- denotes an anion, andn is 0 or 1,with the proviso that if n is O, R.sub.1 is other than an oxo group and R.sub.1 ' and R.sub.2 ' form together a double bond, and with the further provisos that if n is 1, R.sub.1 represents an oxo group and the symbols R.sub.1 ' and R.sub.2 ' are not present, and if Z is a buta-1,3-dienyl group and R.sub.1 denotes an oxo group, R.sub.3 is other than unsubstituted phenyl.The new compounds of the general formula (I) can be prepared by cyclizing the compounds of the general formula (II) or (V), wherein R.sub.1, Z, R.sub.3 and X.sup.- have the above defined meanings, R.sub.4 is a leaving group and R.sub.7 represents hydrogen or C.sub.1-10 alkyl.The new compounds of the general formula (I) possess a valuable antidepressant effect and can advantageously be used in the therapy.

    摘要翻译: 本发明涉及通式(I)的新的缩合的三嗪衍生物,其中Z代表丁-1,3-二烯基或式(a),(b),( c)或(d)R1表示任选被一个或多个相同的C 1-6烷基,氧代基或C 6-10芳基或C 6-10芳基 - (C 1-3烷基) 或选自氨基,硝基,C 1-6烷基,C 1-6烷氧基,羟基和卤素的不同取代基,R 2代表氢,C 1-10烷基或氨基,R 3表示氢,C 1-10烷基或C 6- 芳基或任选被一个或多个相同或不同的选自硝基,氨基,C 1-6烷基,C 1-6烷氧基,羟基和卤素的取代基取代的芳基或C 6-10芳基 - (C 1-3烷基) 表示阴离子,n为0或1,条件是如果n为O,则R1不是氧代基,R1'和R2'一起形成双键,另外条件是,如果n为1, R1代表氧代基团, mbols R1'和R2'不存在,并且如果Z是丁-1,3-二烯基并且R 1表示氧代基,则R 3不是未取代的苯基。 通式(I)的新化合物可以通过使通式(II)或(V)的化合物环化来制备,其中R1,Z,R3和X具有上述定义,R4是离去基团, R 7表示氢或C 1-10烷基。 通式(I)的新化合物具有有价值的抗抑郁作用,可有利地用于治疗。